Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: BRTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.86% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.81M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta -0.52 | 52 Weeks Range 1.21 - 2.55 | Updated Date 09/16/2025 |
52 Weeks Range 1.21 - 2.55 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1089.78% |
Management Effectiveness
Return on Assets (TTM) -66.42% | Return on Equity (TTM) -137.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -984509 | Price to Sales(TTM) 19.51 |
Enterprise Value -984509 | Price to Sales(TTM) 19.51 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 7978120 | Shares Floating 5627285 |
Shares Outstanding 7978120 | Shares Floating 5627285 | ||
Percent Insiders 24.02 | Percent Institutions 8.77 |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies, Inc. is a biotechnology company focused on stem cell therapies. Founded in 2006, it has focused on developing treatments for metabolic and disc/spine disorders.
Core Business Areas
- Metabolic Program (ThermoStem): Uses stem cells to address metabolic disorders. Currently, focuses on type II diabetes. Clinical trials are ongoing.
- Disc/Spine Program (BRTX-100): Utilizes autologous stem cells to treat chronic lower back pain from degenerative disc disease (DDD). Clinical trials are ongoing.
Leadership and Structure
The company has a CEO, CFO, and a scientific advisory board. Organizational structure is typical of a clinical-stage biotechnology company.
Top Products and Market Share
Key Offerings
- BRTX-100: An autologous stem cell therapy for disc degeneration-related lower back pain. It's in clinical trials, so no market share or revenue yet. Competitors include companies developing pain management drugs and spinal fusion alternatives. Key competitors include Medtronic (MDT) and NuVasive (NUVA).
- ThermoStem: A stem cell therapy to improve metabolic function to treat metabolic syndrome and type 2 diabetes. It's in clinical trials, so no market share or revenue yet. Competitors include pharmaceutical companies that target treating Diabetes like Novo Nordisk (NVO) and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The regenerative medicine and cell therapy industry is growing rapidly, driven by aging populations and unmet medical needs. Regulatory pathways are evolving.
Positioning
BioRestorative Therapies is positioned as a clinical-stage company focused on stem cell therapies for specific indications. Their success depends on positive clinical trial results and regulatory approval.
Total Addressable Market (TAM)
The TAM for chronic lower back pain and diabetes treatments is substantial, estimated at billions of dollars annually. BioRestorative's ability to capture market share depends on efficacy, safety, and pricing.
Upturn SWOT Analysis
Strengths
- Proprietary stem cell technology
- Focus on unmet medical needs
- Experienced scientific team
- Clear regulatory pathway outlined by FDA
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trials
- Limited financial resources
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to new indications
- FDA approval of BRTX-100 and/or ThermoStem
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- MDT
- NUVA
- NVO
- LLY
Competitive Landscape
BioRestorative Therapies faces intense competition from established pharmaceutical and medical device companies. Its competitive advantage lies in its stem cell technology and focus on specific indications.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by advancement of clinical programs and expansion of IP portfolio rather than revenue.
Future Projections: Future growth is highly dependent on successful clinical trials and subsequent commercialization of therapies. Analyst estimates are speculative until product approval.
Recent Initiatives: Recent initiatives likely involve progressing clinical trials, seeking partnerships, and securing financing.
Summary
BioRestorative Therapies is a high-risk, high-reward clinical-stage biotech company. Its stem cell technology holds promise, but success hinges on positive clinical trial outcomes and regulatory approvals. The company needs to carefully manage its cash burn and seek strategic partnerships to support its growth. Competition from established players poses a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market share estimates are approximate and subject to change. Investing in clinical-stage biotechnology companies is highly speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.